All In Biotech

NDA 011963 · Fera Pharms LLC

Phospholine Iodide

Echothiophate Iodide · Ophthalmic

Novel

Last checked: Nov 19, 2026Latest source record: Oct 28, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1960

Jun 27, 1960

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2

0 Phase 3, 0 recruiting

FAERS reports

147

75 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 7, 2025.

INDICATIONS AND USAGE Reduction of Elevated IOP Echothiophate iodide for ophthalmic solution is indicated for the reduction of elevated IOP. Accommodative Esotropia Concomitant esotropias with a significant accommodative component.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 27, 1960 Original approval · Type 1 - New Molecular Entity
4 products under this application
  • PHOSPHOLINE IODIDE · ECHOTHIOPHATE IODIDE 0.06% · FOR SOLUTION, OPHTHALMIC · Discontinued
  • PHOSPHOLINE IODIDE · ECHOTHIOPHATE IODIDE 0.03% · FOR SOLUTION, OPHTHALMIC · Discontinued
  • PHOSPHOLINE IODIDE · ECHOTHIOPHATE IODIDE 0.25% · FOR SOLUTION, OPHTHALMIC · Discontinued
  • PHOSPHOLINE IODIDE · ECHOTHIOPHATE IODIDE 0.125% · FOR SOLUTION, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Echothiophate Iodide" as an intervention, any sponsor and status, largest first.

All 2 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • intraocular pressure increased27
  • drug ineffective22
  • visual impairment17
  • eye pain13
  • visual acuity reduced10
  • blindness9
  • blindness unilateral8
  • ocular hyperaemia8
  • eye disorder7
  • eye irritation7
  • vision blurred7
  • glaucoma6

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20075
20084
20091
20109
20119
20129
201311
201420
20159
20166
20177
20184
20198
202025
202110
20223
20233
20242
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 2, 2026

    Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05). Available through limited distribution by Walgreens Specialty Pharmacy.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Phospholine Iodide (Echothiophate Iodide)

2024 spending

$1.1M

Beneficiaries

59

437 claims

Per beneficiary

$19,153

$514.82 per unit

View as table
YearSpending
2020$0
2021$0
2022$341,512
2023$941,693
2024$1,130,040

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5 on PubMed

Sponsor: Fera Pharms LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.